Selskabets formål er at udøve virksomhed indenfor fabrikation, udvikling og handel med veterinære produkter samt al virksomhed, som efter bestyrelsens skøn har forbindelse hermed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 424.9 mio. | 12.2 mio. | 149.1 mio. | 61.5 mio. | 39 | |
CVR: 46290828
Secondary names: HOECHST ROUSSEL VET A/S, INTERVET DANMARK/SCHERING-PLOUGH A/S, INTERVET/SCHERING-PLOUGH ANIMAL HEALTH A/S
Previous names: PROPRIAS PRODUKTER ApS, INTERVET SCANDINAVIA A/S, INTERVET DANMARK A/S
Compared to 406 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Dionna Kathleen Litvin joined the board
Michel Deinum left the board
The financial health of MSD Animal Health A/S appears stable, with a slight increase in revenue from 422.9 million DKK in 2023 to 424.9 million DKK in 2024, although profit has decreased from 14.1 million DKK to 12.2 million DKK during the same period. Over the past three years, revenue has shown a consistent upward trend, rising from 363.7 million DKK in 2022, while profit margins have fluctuated, indicating potential concerns regarding operational efficiency. The company's equity has decreased from 63.3 million DKK in 2023 to 61.5 million DKK in 2024, suggesting a weakening financial position. Overall, MSD Animal Health A/S maintains a solid presence in the pharmaceutical wholesale industry, but its declining profit and equity levels warrant close monitoring.
AI-generated summary
Companies in the same industry and area
companydata.dk